AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczema

AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD). The clinical will be conducted by dermatologist Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.

AXIM's CEO, Dr. George Anastassov, states, "We are extremely pleased that our ongoing efforts in finding solutions to conditions for which there are no effective treatments or the ones available are associated with significant side effects (e.g. immunosuppression) are culminating with the clinical trials of our Renecann product. Psoriasis and atopic dermatitis are debilitating conditions causing significant decrease in quality of life. Utilizing our proprietary technologies and incorporating unique cannabinoids, we believe that we will be able to effectively address these concerns."

Lekhram Changoer MSc, BSc, AXIM Chief Technology Officer, states, "We are very excited to begin human dermatological trials for psoriasis and eczema at The Maurits Clinics. Dr. Meinardi is a highly experienced professional and we are glad that his interests are aligned with ours in the utilization of different cannabinoids as the API for finding safe solutions for people with these skin disorders. The AXIM AX-1602 ointment will be tested with different concentrations of cannabinoids and will be placebo controlled.  Following the successful completion of this clinical trial, AXIM® products will be registered as an ointment for various skin disorders."